Catalent Completes Acquisition of MaSTherCell
February 10 2020 - 4:15PM
Business Wire
Catalent, Inc. (NYSE: CTLT), the leading global provider of
advanced delivery technologies, development, and manufacturing
solutions for drugs, biologics, cell and gene therapies, and
consumer health products, today announced that it had completed its
acquisition of MaSTherCell Global Inc., positioning Catalent as a
premier technology, development and manufacturing partner for
innovators of advanced biotherapeutics.
With the addition of MaSTherCell’s unique portfolio of
capabilities, technologies, and related analytical services
spanning both autologous and allogeneic cell therapies, Catalent is
well positioned to lead the industry with its cell & gene
therapy platforms.
The acquisition adds to Catalent’s network MaSTherCell’s 25,000
square-foot clinical services facility in Gosselies, Belgium, and
its 32,000 square-foot facility in Houston, Texas, which is focused
on development-scale projects and is scheduled to open later this
quarter. Catalent will leverage its resources and expertise in
build-outs, scale-ups and commercial manufacturing to support the
expansion already underway of a 60,000 square-foot commercial-scale
cell therapy production and fill-finish facility adjacent to the
existing building in Gosselies, which is scheduled to open in the
fall of 2021.
Catalent financed the acquisition with the proceeds of an
underwritten public offering of its common stock completed last
week.
Notes for Editors
About Catalent
Catalent, Inc. (NYSE: CTLT) is the leading global provider of
advanced delivery technologies, development, and manufacturing
solutions for drugs, biologics, cell and gene therapies, and
consumer health products. With over 85 years serving the industry,
Catalent has proven expertise in bringing more customer products to
market faster, enhancing product performance and ensuring reliable
global clinical and commercial product supply. Catalent employs
over 13,000 people, including over 2,400 scientists and
technicians, at more than 35 facilities, and in fiscal year 2019
generated over $2.5 billion in annual revenue. Catalent is
headquartered in Somerset, New Jersey. For more information, visit
www.catalent.com
More products. Better treatments. Reliably supplied.™
Forward-Looking Statement Notice
This release contains both historical and forward-looking
statements. All statements other than statements of historical fact
are, or may be deemed to be, forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended,
including statements concerning MaSTherCell’s future growth and
prospects, its integration into Catalent, and the growth and
prospects of the markets in which MaSTherCell’s customers operate.
These forward-looking statements generally can be identified by the
use of statements that include phrases such as “believe,” “expect,”
“anticipate,” “intend,” “estimate,” “plan,” “project,” “foresee,”
“likely,” “may,” “will,” “would” or other words or phrases with
similar meanings. Similarly, statements that describe the Company’s
objectives, plans or goals are, or may be, forward-looking
statements. These statements are based on current expectations of
future events. If underlying assumptions prove inaccurate or
unknown risks or uncertainties materialize, actual results could
vary materially from Catalent, Inc.’s expectations and projections.
Some of the factors that could cause actual results to differ
include, but are not limited to, the following: participation in a
highly competitive market and increased competition may adversely
affect the business of the Company; demand for the Company’s
offerings, which depends in part on the Company’s customers’
research and development and the clinical and market success of
their products; product and other liability risks that could
adversely affect the Company’s results of operations, financial
condition, liquidity and cash flows; failure to comply with
existing and future regulatory requirements; failure to provide
quality offerings to customers could have an adverse effect on the
Company’s business and subject it to regulatory actions and costly
litigation; problems providing the highly exacting and complex
services or support required; global economic, political and
regulatory risks to the operations of the Company; inability to
enhance existing or introduce new technology or service offerings
in a timely manner; inadequate patents, copyrights, trademarks and
other forms of intellectual property protections; fluctuations in
the costs, availability, and suitability of the components of the
products the Company manufactures, including active pharmaceutical
ingredients, excipients, purchased components and raw materials;
changes in market access or healthcare reimbursement in the United
States or internationally; fluctuations in the exchange rate of the
U.S. dollar against other currencies, including as a result of the
U.K.’s pending exit from the European Union; adverse tax
legislative or regulatory initiatives or challenges or adjustments
to the Company’s tax positions; loss of key personnel; risks
generally associated with information systems; inability to
complete any future acquisition or other transaction that may
complement or expand the Company’s business or divestment of
non-strategic businesses or assets and difficulties in successfully
integrating acquired businesses and realizing anticipated benefits
of such acquisitions; risks associated with timely and successfully
completing, and correctly anticipating the future demand predicted
for, capital expansion projects at our existing or any acquired
facilities, offerings and customers’ products that may infringe on
the intellectual property rights of third parties; environmental,
health and safety laws and regulations, which could increase costs
and restrict operations; labor and employment laws and regulations
or labor difficulties, which could increase costs or result in
operational disruptions; additional cash contributions required to
fund the Company’s existing pension plans; substantial leverage
resulting in the limited ability of the Company to raise additional
capital to fund operations and react to changes in the economy or
in the industry, exposure to interest-rate risk to the extent of
the Company’s variable-rate debt, and preventing the Company from
meeting its obligations under its indebtedness; adverse market
conditions that interfere with the ability of the Company to access
the capital markets; and lack of market interest in the Company’s
capital offerings. For a more detailed discussion of these and
other factors, see the information under the caption “Risk Factors”
in the Company’s Annual Report on Form 10-K for the fiscal year
ended June 30, 2019, filed August 27, 2019. All forward-looking
statements speak only as of the date of this release or as of the
date they are made, and Catalent, Inc. does not undertake to update
any forward-looking statement as a result of new information or
future events or developments except to the extent required by
law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200210005766/en/
Media: Chris Halling +44 (0) 7580
041073 chris.halling@catalent.com Richard Kerns
+44 (0) 161 728 5880 richard@nepr.agency
Investors: Paul Surdez (732) 537-6325
investors@catalent.com
Catalent (NYSE:CTLT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Catalent (NYSE:CTLT)
Historical Stock Chart
From Sep 2023 to Sep 2024